Levothyroxine iv administration

The IV dose should be reduced to 70% or less of the usual oral dose. For example, if a patient was receiving 100 micrograms of oral levothyroxine the dose of IV levothyroxine would be 70 micrograms. See table below for suggested dose conversions for ease of administration. Oral levothyroxine dose IV levothyroxine dose 50 micrograms 35 micrograms

Characterizing unnecessary IV levothyroxine use Quantifying the number of inappropriate doses avoided with protocol implementation Secondary Outcomes 5-day hold from last levothyroxine administration before starting IV levothyroxine if oral or enteral administration is not possible Enteral administration of levothyroxine if patient has

The nurse has a vial of 200 mcg levothyroxine powder for injection. The following information is in the drug reference: IV Administration IV

The IV dose should be reduced to 70% or less of the usual oral dose. For example, if a patient was receiving 100 micrograms of oral levothyroxine the dose of IV levothyroxine would be 70 micrograms. See table below for suggested dose conversions for ease of administration. Oral levothyroxine dose IV levothyroxine dose 50 micrograms 35 micrograms

The IV dose should be reduced to 70% or less of the usual oral dose. For example, if a patient was receiving 100 micrograms of oral levothyroxine the dose of IV levothyroxine would be 70 micrograms. See table below for suggested dose conversions for ease of administration. Oral levothyroxine dose IV levothyroxine dose 50 micrograms 35 micrograms

See table below for suggested dose conversions for ease of administration. Oral levothyroxine dose. IV levothyroxine dose. 50 micrograms. 35 micrograms. 75

Levothyroxine Sodium Lyophilized Powder Injection 100mcg/vl SDV 5mL/Vl IV Administration and Infusion Sets IV Catheters IV Solutions Kenalog

Levothyroxine Sodium Lyophilized Powder Injection 100mcg/vl SDV 5mL/Vl IV Administration and Infusion Sets IV Catheters IV Solutions Kenalog

safe. The conversion of the IV levothyroxine dose to an oral dose has been already discussed in Section 5 of this memorandum. It should be also recognized that transition from IV levothyroxine to oral administration during the treatment of myxedema coma is different from converting an oral levothyroxine product to